High-Dose Continuous Propofol for Refractory Hyperactive Delirium: A Case Report
Journal of Palliative Care · 29.03.2026
DOI: 10.1177/08258597261436878 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Palliative Care, online erschienen am 29.03.2026. Verfasst von Susana Marques-Martins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Acute Palliative Care Inpatient Unit, Santa Maria Local Health Unit, Lisboa, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Themen: Delir
Abstract (Originalsprache)
Background
Delirium is a frequent and distressing complication in advanced cancer, often multifactorial and refractory to standard agents. Palliative sedation may be required when symptoms remain uncontrolled, and propofol is an emerging option in this context. Case Presentation We describe a 61-year-old woman with Stage IV lung adenocarcinoma admitted to a hospice-type palliative care (PC) unit. She had multiple comorbidities and a history of polysubstance use, including long-term methadone and benzodiazepines. On Day 7, she developed hyperactive delirium unresponsive to escalating neuroleptics, benzodiazepines, and barbiturates, consistent with “pharmacoresistant” delirium. Management/Intervention After multidisciplinary review and discussion with her son, proportional PS was initiated using continuous intravenous propofol infusion. The infusion began at 60 mg/h (1.5 mg/kg/h) and gradually titrated to 320 mg/h (≈8 mg/kg/h). Concurrently, transdermal fentanyl was increased to 300 µg/h for analgesia. Sedation depth was monitored with the “Consciousness Scale for PC,” with goals set at Levels 1–3 to allow intermittent interaction. Outcomes Adequate sedation was achieved within 10 min and maintained for 25 days until death, without respiratory or hemodynamic compromise. No adverse effects or signs of propofol infusion syndrome were observed, despite doses exceeding conventional thresholds.
Conclusion
This case highlights the feasibility and safety of high-dose, long-term propofol infusion for refractory delirium in advanced cancer. While not routine, propofol may serve as a rescue agent when standard regimens fail, provided decisions are ethically grounded, monitoring is rigorous, and family involvement is prioritized.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Acute Palliative Care Inpatient Unit, Santa Maria Local Health Unit, Lisboa, Portugal.
- Center for Palliative Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
- Bento Menni Palliative Care Unit, Idanha Health Center, Sintra, Portugal.
ORCID-Profile: Paulo Reis-Pina
Zitieren
APA
Marques-Martins, S., Miguel-Freitas, B., Domingues-Oliveira, F., & Reis-Pina, P. (2026). High-Dose Continuous Propofol for Refractory Hyperactive Delirium: A Case Report. Journal of Palliative Care. https://doi.org/10.1177/08258597261436878
Vancouver
Marques-Martins S, Miguel-Freitas B, Domingues-Oliveira F, Reis-Pina P. High-Dose Continuous Propofol for Refractory Hyperactive Delirium: A Case Report. Journal of Palliative Care. 2026. doi:10.1177/08258597261436878
BibTeX
@article{MarquesMartins2026,
author = {Marques-Martins, Susana and Miguel-Freitas, Bruno and Domingues-Oliveira, Fátima and Reis-Pina, Paulo},
title = {High-Dose Continuous Propofol for Refractory Hyperactive Delirium: A Case Report},
journal = {Journal of Palliative Care},
year = {2026},
doi = {10.1177/08258597261436878}
}
EUVIMED